127 related articles for article (PubMed ID: 33104983)
1. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study.
Tao Y; E M; Shi J; Zhang Z
Aging Clin Exp Res; 2021 Aug; 33(8):2133-2139. PubMed ID: 33104983
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
[TBL] [Abstract][Full Text] [Related]
3. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus.
Lapane KL; Jesdale BM; Dubé CE; Pimentel CB; Rajpathak SN
Diabetes Res Clin Pract; 2015 Aug; 109(2):411-9. PubMed ID: 26008723
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes.
Rajpathak SN; Fu C; Brodovicz KG; Engel SS; Lapane K
Drugs Aging; 2015 Apr; 32(4):321-7. PubMed ID: 25825122
[TBL] [Abstract][Full Text] [Related]
5. Sulfonylureas and risk of falls and fractures: a systematic review.
Lapane KL; Yang S; Brown MJ; Jawahar R; Pagliasotti C; Rajpathak S
Drugs Aging; 2013 Jul; 30(7):527-47. PubMed ID: 23609875
[TBL] [Abstract][Full Text] [Related]
6. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
7. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
8. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
9. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
10. Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Chen YH; Du L; Geng XY; Peng YL; Shen JN; Zhang YG; Liu GJ; Sun X
J Evid Based Med; 2015 Aug; 8(3):134-48. PubMed ID: 26066789
[TBL] [Abstract][Full Text] [Related]
11. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
15. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
16. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
Azoulay L; Suissa S
Diabetes Care; 2017 May; 40(5):706-714. PubMed ID: 28428321
[TBL] [Abstract][Full Text] [Related]
17. Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study.
Majumdar SR; Josse RG; Lin M; Eurich DT
J Clin Endocrinol Metab; 2016 May; 101(5):1963-9. PubMed ID: 26930183
[TBL] [Abstract][Full Text] [Related]
18. Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes.
Starup-Linde J; Gregersen S; Frost M; Vestergaard P
Bone; 2017 Feb; 95():136-142. PubMed ID: 27890548
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
Wolverton D; Blair MM
Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review.
Chen Y; Du L; Li L; Ma J; Geng X; Yao X; Liu G; Sun X
J Diabetes; 2017 May; 9(5):482-494. PubMed ID: 27273872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
